Huntingtons disease mice infected with toxoplasma gondii demonstrate early kynurenine pathway activation, altered CD8+ T-Cell responses, and premature mortality

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Donley, David W ^a   Olson, Andrew R ^a   Raisbeck, Merl F ^a   Fox, Jonathan H ^a   Gigley, Jason P ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; BIOLOGICAL MARKER;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; FRONTAL CORTEX; HUNTINGTON CHOREA; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MORTALITY RATE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARASITE LOAD; PHENOTYPE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; STRIATE CORTEX; SURVIVAL RATE; TOXOPLASMOSIS; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MORTALITY; PARASITOLOGY; PATHOLOGY; PREMATURE MORTALITY; TOXOPLASMA;

ANIMALS; BIOMARKERS; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUNTINGTON DISEASE; IMMUNOPHENOTYPING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LYMPHOCYTE ACTIVATION; MICE; MORTALITY, PREMATURE; PARASITE LOAD; PHENOTYPE; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84991000295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162404     Document Type: Article

References (44)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72(6):971-83. Epub 1993/03/26. PMID: 8458085.
2. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006; 127 (1):59-69. PMID: 17018277.
3. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain: a journal of neurology. 2007; 130(Pt 7):1759-66. Epub 2007/04/03. doi: 10.1093/brain/awm044 PMID: 17400599.
4. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of experimental medicine. 2008; 205(8):1869-77. Epub 2008/07/16. doi: 10.1084/jem.20080178 PMID: 18625748; PubMed Central PMCID: PMCPmc2525598.
5. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A. 2004; 101(10):3498-503. PMID: 14993615.
6. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001; 60 (2):161-72. PMID: 11273004.
7. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 2011; 32(2):258-70. doi: 10.1002/hbm.21008 PMID: 21229614
8. Weiss A, Trager U, Wild EJ, Grueninger S, Farmer R, Landles C, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest. 2012; 122(10):3731-6. doi: 10. 1172/JCI64565 PMID: 22996692; PubMed Central PMCID:PMCPMC3461928.
9. Trager U, Andre R, Lahiri N, Magnusson-Lind A,Weiss A, GrueningerS, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain: a journal of neurology. 2014; 137(Pt 3):819-33. doi: 10.1093/brain/awt355 PMID: 24459107; PubMed Central PMCID:PMCPMC3983408.
10. Politis M, Lahiri N, Niccolini F, Su P, Wu K, GiannettiP, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of disease. 2015; 83:115-21. doi: 10.1016/j.nbd.2015.08.011 PMID: 26297319.
11. Trager U, Andre R, Magnusson-Lind A, Miller JR, Connolly C,Weiss A, et al. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of disease. 2014; 73C:388-98. doi: 10.1016/j.nbd.2014.10.012 PMID: 25447230; PubMed Central PMCID:PMCPMC4262574.
12. Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol. 2001; 154(4):357-65. PMID: 11495859.
13. HermesG, Ajioka JW, Kelly KA, Mui E, RobertsF, Kasza K, et al. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation,and neuronal injury in brains of mice due to common, persistent, parasitic infection. Journal of neuroinflammation. 2008; 5:48. Epub 2008/10/25. doi: 10.1186/1742-2094-5-48 PMID: 18947414; PubMed Central PMCID: PMCPmc2588578.
14. Suzuki Y, Orellana MA, SchreiberRD, Remington JS. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science. 1988; 240(4851):516-8. PMID: 3128869.
15. Fujigaki S, Saito K, Takemura M, Maekawa N, Yamada Y, Wada H, et al. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferongene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infection and immunity. 2002; 70(2):779-86. PMID: 11796611; PubMed Central PMCID: PMCPMC127656.
16. Gupta SL, Carlin JM, Pyati P, DaiW, Pfefferkorn ER, Murphy MJ Jr. Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts. Infection and immunity. 1994; 62(6):2277-84. PMID: 8188349; PubMed Central PMCID:PMCPMC186508.
17. MacKenzie CR, Gonzalez RG, Kniep E, Roch S, DaubenerW. Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med Biol. 1999; 467:533-9. PMID: 10721097.
18. Guidetti P, Luthi-CarterRE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiology of disease. 2004; 17(3):455-61. doi: 10. 1016/j.nbd.2004.07.006 PMID: 15571981.
19. Campesan S, GreenEW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Current biology: CB. 2011; 21(11):961-6. Epub 2011/06/04. doi: 10.1016/j.cub.2011.04.028 PMID: 21636279; PubMed Central PMCID: PMCPmc3929356.
20. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011; 145(6):863-74. Epub 2011/06/07. doi: 10.1016/j.cell.2011.05.020 PMID: 21640374; PubMed Central PMCID: PMCPmc3118409.
21. Lu Z, Marks E, Chen J, Moline J, Barrows L, Raisbeck M, et al. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model. Neurobiology of disease. 2014; 71:34-42. Epub 2014/07/12. doi: 10.1016/j.nbd.2014.06.022 PMID: 25014023.
22. Schilling G, BecherMW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.Hum Mol Genet. 1999; 8(3):397-407. PMID: 9949199.
23. Gigley JP, Fox BA, Bzik DJ. Long-termimmunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain. Infection and immunity. 2009; 77(12):5380-8. doi: 10.1128/IAI.00649-09 PMID: 19797073; PubMed Central PMCID:PMCPMC2786442.
24. Braun D, LongmanRS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood. 2005; 106(7):2375-81. doi: 10.1182/blood-2005-03-0979 PMID: 15947091; PubMed Central PMCID: PMC1895261.
25. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferongamma primed mononuclear phagocytes. J Biol Chem. 1994; 269(20):14457-64. PMID: 7514170.
26. Bhadra R, Gigley JP, Weiss LM, Khan IA. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci U S A. 2011; 108(22):9196-201. Epub 2011/05/18. doi: 10.1073/pnas.1015298108 PMID: 21576466; PubMed Central PMCID: PMCPmc3107287.
27. Bhadra R, Gigley JP, Khan IA. PD-1-mediated attrition of polyfunctional memoryCD8+ T cells in chronic toxoplasma infection. J Infect Dis. 2012; 206(1):125-34. doi: 10.1093/infdis/jis304 PMID: 22539813; PubMed Central PMCID:PMCPMC3415930.
28. Gigley JP, Fox BA, Bzik DJ. Cell-mediated immunity to Toxoplasma gondii develops primarilyby local Th1 host immune responses in the absence of parasite replication. Journal of immunology (Baltimore, Md: 1950). 2009; 182(2):1069-78. PMID: 19124750; PubMed Central PMCID:PMCPMC2615398.
29. Chew WK,Wah MJ, Ambu S, Segarra I. Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts. Exp Parasitol. 2012; 130(1):22-5. doi: 10.1016/j. exppara.2011.10.004 PMID: 22027550.
30. Khan IA, Green WR, Kasper LH, Green KA, Schwartzman JD. Immune CD8(+) T cells prevent reactivation of Toxoplasma gondii infection in the immunocompromised host. Infection and immunity. 1999; 67 (11):5869-76. PMID: 10531242; PubMed Central PMCID:PMCPMC96968.
31. Sutterland AL, Fond G, Kuin A, KoeterMW, Lutter R, van Gool T, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-Analysis. Acta Psychiatr Scand. 2015; 132(3):161-79. doi: 10.1111/acps.12423 PMID: 25877655.
32. MimanO, Kusbeci OY, Aktepe OC, Cetinkaya Z. The probable relation between Toxoplasma gondii and Parkinson's disease. Neurosci Lett. 2010; 475(3):129-31. Epub 2010/03/31. doi: 10.1016/j.neulet. 2010.03.057 PMID: 20350582.
33. Celik T, KamisliO, Babur C, Cevik MO, Oztuna D, Altinayar S. Is there a relationship between Toxoplasma gondii infection and idiopathic Parkinson's disease? Scandinavian journal of infectious diseases. 2010; 42(8):604-8. Epub 2010/04/13. doi: 10.3109/00365541003716500 PMID: 20380545.
34. Kusbeci OY, MimanO, Yaman M, Aktepe OC, Yazar S. Could Toxoplasma gondii have any role in Alzheimer disease? Alzheimer Dis Assoc Disord. 2011; 25(1):1-3. PMID: 20921875. doi: 10.1097/WAD. 0b013e3181f73bc2
35. Perry CE, Gale SD, Erickson L, Wilson E, Nielsen B, Kauwe J, et al. Seroprevalence and Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without Alzheimer Disease. Alzheimer Dis Assoc Disord. 2016; 30(2):123-6. Epub 2015/10/01. doi: 10.1097/wad.0000000000000108 PMID: 26421353.
36. DuanW, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiology of disease. 2008; 30(3):312-22. PMID: 18403212. doi: 10.1016/j.nbd.2008.01.015
37. Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Experimental neurology. 2004; 187(1):137-49. doi: 10.1016/j.expneurol.2004.01.003 PMID: 15081595.
38. Miller JR, Trager U, Andre R, Tabrizi SJ. Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes. PloS one. 2015; 10(11):e0141793. doi: 10.1371/journal. pone.0141793 PMID: 26529236; PubMed Central PMCID:PMCPMC4631523.
39. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13(7):465-77. PMID: 22678511. doi: 10.1038/nrn3257
40. Mazarei G, Budac DP, Lu G, Adomat H, Tomlinson Guns ES, Moller T, et al. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. Journal of neurochemistry. 2013; 127(6):852-67. Epub 2013/06/22. doi: 10.1111/jnc.12350 PMID: 23786539.
41. Mezrich JD, Fechner JH, Zhang X, Johnson BP, BurlinghamWJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatoryT cells. Journal of immunology (Baltimore, Md: 1950). 2010; 185(6):3190-8. doi: 10.4049/jimmunol.0903670 PMID: 20720200; PubMed Central PMCID:PMCPMC2952546.
42. CarterCJ. Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders. J Pathog. 2013; 2013:965046. doi: 10.1155/2013/965046 PMID: 23533776; PubMed Central PMCID: PMCPMC3603208.
43. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000; 97(12):6763-8. PMID: 10823891.
44. Boussicault L, Alves S, Lamaziere A, Planques A, Heck N, Moumne L, et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease. Brain: a journal of neurology. 2016; 139(Pt 3):953-70. doi: 10.1093/brain/awv384 PMID: 26912634; PubMed Central PMCID: PMCPMC4766376.